Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.1 (
asparaginase
)
2,695
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
L-asparaginase
is one of the most important agent used in multidrug chemotherapy regimens in the treatment of malignancies which derive from lymphoid system (acute lymhoblastic leukemias and non-hodgkin lymphoma).
L-asparaginase
leads to enzymatic cleavage of L-asparagine (amino acid essential for lymphoblasts' growth) to ammonia and L-aspartic acid, what results in depletion of L-asparagine in a serum and cerebrospinal fluid, and finally leads to destruction of lymphoblasts, which lack ability of endogenic L-asparagine production. In the course of
L-asparaginase
therapy severe side effects could be observed such as: coagulation disturbances, acute pancreatitis, anaphilactic shock and other types of allergic reaction, as well as liver and CNS failure. Monitoring of
L-asparaginase
activity in serum is recomended in order to optimalize therapy with
L-asparaginase
and reducing risk of severe side effects. Continuous assessment of
L-asparaginase
activity during therapy gives also opportunity to detect asymptomatic inactivation of L-
ASPA
- so called "silent inactivation", which is cused by production of antibodies against xenogenic protein, especcialy in IgG class. This process leads to shortening of half-life of L-
ASPA
. The paper shows presently available monitoring methods during therapy with L-
ASPA
, with all their pros and cons.
...
PMID:[Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia]. 1689
